322 related articles for article (PubMed ID: 9193323)
1. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain SM; Whaley FS; Gerber MC; Weisberg S; York M; Spicer D; Jones SE; Wadler S; Desai A; Vogel C; Speyer J; Mittelman A; Reddy S; Pendergrass K; Velez-Garcia E; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1318-32. PubMed ID: 9193323
[TBL] [Abstract][Full Text] [Related]
2. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
6. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
[No Abstract] [Full Text] [Related]
7. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
[TBL] [Abstract][Full Text] [Related]
10. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
11. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
Lopez M; Vici P; Di Lauro K; Conti F; Paoletti G; Ferraironi A; Sciuto R; Giannarelli D; Maini CL
J Clin Oncol; 1998 Jan; 16(1):86-92. PubMed ID: 9440727
[TBL] [Abstract][Full Text] [Related]
12. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
[TBL] [Abstract][Full Text] [Related]
13. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Jelić S; Radulović S; Nesković-Konstantinović Z; Kreacić M; Ristović Z; Bosnjak S; Milanović N; Vuletić L
Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced cardiomyopathy.
Swain SM
N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
[No Abstract] [Full Text] [Related]
19. [The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Lichinitser MR; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Ter Arkh; 1994; 66(7):54-6. PubMed ID: 7985130
[No Abstract] [Full Text] [Related]
20. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]